1. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
- Author
-
Koehler, Philipp, Bassetti, Matteo, Chakrabarti, Arunaloke, Chen, Sharon CA, Colombo, Arnaldo Lopes, Hoenigl, Martin, Klimko, Nikolay, Lass-Flörl, Cornelia, Oladele, Rita O, Vinh, Donald C, Zhu, Li-Ping, Böll, Boris, Brüggemann, Roger, Gangneux, Jean-Pierre, Perfect, John R, Patterson, Thomas F, Persigehl, Thorsten, Meis, Jacques F, Ostrosky-Zeichner, Luis, White, P Lewis, Verweij, Paul E, Cornely, Oliver A, European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, and Infectious Disease Canada
- Subjects
European Confederation of Medical Mycology ,International Society for Human Animal Mycology ,Asia Fungal Working Group ,INFOCUS LATAM/ISHAM Working Group ,ISHAM Pan Africa Mycology Working Group ,European Society for Clinical Microbiology ,Infectious Diseases Fungal Infection Study Group ,ESCMID Study Group for Infections in Critically Ill Patients ,Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy ,Medical Mycology Society of Nigeria ,Medical Mycology Society of China Medicine Education Association ,Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology ,Association of Medical Microbiology ,Infectious Disease Canada ,Clinical Sciences ,Medical Microbiology ,Public Health and Health Services ,Microbiology - Abstract
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
- Published
- 2021